Resveratrol vs Berberine: Longevity Pathways Compared

Berberine has significantly stronger clinical evidence (metabolic outcomes). Resveratrol's longevity story is compelling but largely preclinical with disappointing human translation. Neither is proven to extend human lifespan.

No direct interaction studies exist. Both activate AMPK and inhibit CYP enzymes, so combining may amplify drug interaction risks. Both lower blood glucose — combining with metformin or diabetes medications risks hypoglycemia. Consult your healthcare provider.

Berberine has multiple meta-analyses for glucose, lipids, and metabolic markers. Resveratrol has hundreds of trials but mostly small, short-term, with inconsistent results. Berberine's evidence is more actionable and replicated.

Blood glucose and lipid management. It reduced HbA1c by ~0.9% (comparable to metformin) and LDL by 20–25% in meta-analyses. These are its strongest, most replicated clinical outcomes.

Resveratrol has <1% oral bioavailability due to rapid phase II metabolism, producing low, transient plasma levels. The dramatic effects seen in mice (running farther, living longer) have not replicated in humans at achievable doses.

Both activate AMPK and lower blood glucose, but through partially different mechanisms. One trial showed berberine comparable to metformin for HbA1c reduction. Berberine is not FDA-approved as a diabetes drug; discuss with your doctor.

Both can cause GI symptoms. Resveratrol at >1g causes GI effects and CYP inhibition. Berberine inhibits CYP3A4/2D6 (significant drug interaction potential) and can cause constipation/GI upset. Berberine's drug interactions are better characterized.

Berberine inhibits CYP3A4, CYP2D6, and P-glycoprotein, affecting many medications (cyclosporine, digoxin, macrolides, some statins). It also additively lowers glucose with diabetes drugs. Always check interactions with your pharmacist.

Resveratrol was initially reported as a SIRT1 activator, but subsequent studies questioned the directness of this activation. Some effects may be indirect via AMPK. The sirtuin activation story is more nuanced than early reports suggested.

Berberine has stronger cardiovascular evidence (LDL reduction, glucose control). Resveratrol has mixed cardiovascular trial results. For measurable cardiovascular risk markers, berberine has the stronger clinical data.

Both are affordable. Berberine ~$0.10–0.30/day at 500–1,500 mg. Resveratrol ~$0.10–0.40/day at 100–500 mg (enhanced forms cost more). Costs are comparable at standard doses.

Meta-analysis showed average weight loss of 2.07 kg (4.6 lbs) over 8–12 weeks via AMPK activation. Effects are modest — not a weight-loss drug, but a supportive metabolic intervention.

Berberine: 500 mg 2–3x/day with meals (total 1,000–1,500 mg/day). Resveratrol: 100–500 mg/day (enhanced forms for bioavailability). Doses reflect different compound potencies and half-lives.

Berberine alters gut microbiome composition (reducing Firmicutes, increasing Bacteroidetes) and has antimicrobial properties. Resveratrol has some microbiome effects but less characterized. Berberine's gut effects are better studied.

Dihydroberberine shows 2–5x improved bioavailability over standard berberine. Resveratrol enhanced forms (liposomal, micronized) improve absorption somewhat. Both benefit from formulation optimization.